WO2016026445A1 - 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用 - Google Patents

作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用 Download PDF

Info

Publication number
WO2016026445A1
WO2016026445A1 PCT/CN2015/087556 CN2015087556W WO2016026445A1 WO 2016026445 A1 WO2016026445 A1 WO 2016026445A1 CN 2015087556 W CN2015087556 W CN 2015087556W WO 2016026445 A1 WO2016026445 A1 WO 2016026445A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
unsubstituted
compound
substituted
halogenated
Prior art date
Application number
PCT/CN2015/087556
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
耿美玉
刘磊
江磊
黄敏
查传涛
艾菁
王磊
曹建华
丁健
Original Assignee
上海海和药物研究开发有限公司
中国科学院上海药物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海海和药物研究开发有限公司, 中国科学院上海药物研究所 filed Critical 上海海和药物研究开发有限公司
Priority to ES15833329T priority Critical patent/ES2904544T3/es
Priority to KR1020177007663A priority patent/KR102022866B1/ko
Priority to BR112017003312-7A priority patent/BR112017003312B1/pt
Priority to US15/504,854 priority patent/US10562900B2/en
Priority to AU2015306561A priority patent/AU2015306561B2/en
Priority to CA2958503A priority patent/CA2958503C/en
Priority to EP15833329.4A priority patent/EP3184521B1/en
Priority to KR1020197026420A priority patent/KR102166002B1/ko
Priority to MX2017002206A priority patent/MX2017002206A/es
Priority to MYPI2017000250A priority patent/MY188447A/en
Priority to RU2017105781A priority patent/RU2719428C2/ru
Priority to JP2017509744A priority patent/JP6445684B2/ja
Publication of WO2016026445A1 publication Critical patent/WO2016026445A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention belongs to the field of medicine, and in particular, the present invention relates to a carbazole compound as an FGFR kinase inhibitor, and to the preparation and use thereof.
  • Receptor tyrosine kinase plays a key role in tumor development, invasion and metastasis, drug resistance and other aspects due to its abnormal expression activation or gene mutation. Has become an important target for the development of anti-tumor drugs.
  • fibroblast growth factor receptors FGFRs
  • FGFs Fibroblast Growth Factors Due to gene amplification, mutation, fusion or ligand induction, FGFR members continue to activate, induce tumor cell proliferation, invasion, migration, promote angiogenesis, and promote tumor development.
  • FGFRs are highly expressed and abnormally activated in a variety of tumors, and are closely related to the poor prognosis of cancer patients, such as non-small cell lung cancer, breast cancer, stomach cancer, bladder cancer, endometrial cancer, prostate cancer, cervical cancer, colon cancer, esophageal cancer. , keratinoma, myeloma, rhabdomyosarcoma, etc.
  • cancer patients such as non-small cell lung cancer, breast cancer, stomach cancer, bladder cancer, endometrial cancer, prostate cancer, cervical cancer, colon cancer, esophageal cancer.
  • keratinoma myeloma
  • rhabdomyosarcoma etc.
  • Studies have shown that FGFR1 amplification accounts for 20% of non-small cell lung cancer squamous cell carcinoma, and studies on proliferation and signaling pathways of FGFR1-expanded lung cancer cell lines show that FGFR selective inhibitors can effectively inhibit the activation of FGFR1 signaling pathway.
  • the expansion of the chromosome (8p11–12) region in which FGFR1 is located accounts for approximately 10% of ER-positive patients, and its high expression of FGFR1 mRNA and poor prognosis of patients are associated with FGFR2 gene amplification or mutation leading to FGFR2 signaling.
  • Abnormal activation of the pathway is mainly associated with gastric cancer, triple-negative breast cancer, and endometrial cancer.
  • the expansion rate of FGFR2 in gastric cancer tissues is 5%-10%.
  • FGFR2 amplification accounts for 4% of refractory triple negative breast cancer.
  • Endometrial cancer is a common gynaecological genital tumor, and FGFR2 mutations account for about 12% of endometrial cancer.
  • FGFR3 mutations accounted for 50%-60% in non-invasive bladder cancer, and FGFR3 mutations accounted for 10%-15% in invasive bladder cancer.
  • FGFR3t(4;14)(p16.3;q32) gene rearrangement accounts for 15–20% in multiple myeloma.
  • FGFR and its ligand FGFs of various subtypes in liver cancer have abnormal expression and activation, such as FGFR2, FGFR3, FGFR4, FGF19, FGF2, FGF5, FGF8, FGF9 and the like.
  • a number of preclinical and clinical studies have demonstrated the importance of abnormal activation of the FGF/FGFR axis in liver cancer. It should not be overlooked that abnormal activation of the FGF/FGFR axis is closely related to resistance to EGFR inhibitors, neovascular inhibitors, and endocrine therapy. Therefore, the development of targeted FGFR inhibitors has become a hot topic in the research of anti-tumor drugs.
  • L is selected from the group consisting of H, tetrahydropyranyl (THP);
  • Each X is independently selected from the group consisting of Cl, F, H, CN;
  • W, Y, Z are each independently selected from: N or CH;
  • Ring A is a 5- to 8-membered arylene group which is unsubstituted, substituted or unsubstituted, or a substituted or unsubstituted 5 to 8 membered heteroarylene group, wherein the heteroaryl group contains at least one member selected from the group consisting of a hetero atom: nitrogen, oxygen, or sulfur; a substituted or unsubstituted 3 to 12 membered saturated heterocyclic ring or carbocyclic ring, wherein the heterocyclic ring contains at least one hetero atom selected from the group consisting of nitrogen, oxygen, or sulfur;
  • R is H, or a substituted or unsubstituted group selected from the group consisting of:
  • M is selected from the group consisting of substituted or unsubstituted C1-C6 alkylene, substituted or unsubstituted C6-C10 arylene, substituted or unsubstituted C1-C10 heteroarylene, or M No
  • substitutions means that one or more hydrogen atoms on the above group are substituted with a substituent selected from the group consisting of halogen, unsubstituted or halogenated C1-C6 alkyl, unsubstituted or halogenated C1. -C6 alkoxy, unsubstituted or halogenated C1-C6 alkoxyalkyl, unsubstituted or halogenated C3-C8 cycloalkyl, unsubstituted or halogenated C2-C6 alkylcarbonyl, unsubstituted or Halogenated C1-C6 alkylene-hydroxy, unsubstituted or C1-C6 alkyl substituted amine.
  • the ring A is a heteroaryl group or a saturated heterocyclic ring selected from the group consisting of the following, or the ring A is absent:
  • Q 1 , Q 2 , Q 3 , Q 4 are each independently selected from: N or CH;
  • B 1 , B 2 , B 3 , B 4 are each independently selected from: N or CH.
  • the ring A is a heteroaryl group or a saturated heterocyclic ring selected from the group consisting of the following, or the ring A is absent:
  • R is a substituted or unsubstituted group selected from the group consisting of:
  • R 1 , R 2 , R 3 , R 4 are each independently selected from the group consisting of H, halogen, C1-C6 straight or branched alkyl, halogenated C1-C6 straight or branched alkyl;
  • R 5 is selected from the group consisting of H, C1-C6 straight or branched alkyl, C1-C6 straight or branched alkylcarbonyl, C1-C6 straight or branched alkylene-hydroxy, C1- C6 alkoxyalkyl, unsubstituted or alkyl substituted amine, C1-C8 cycloalkyl.
  • R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 are each independently selected from the group consisting of H, C1-C6 straight or branched alkyl, C1-C6 straight or branched Alkylcarbonyl, C1-C6 straight or branched alcohol group (alkylene-hydroxy);
  • G 1 , G 2 , G 3 , G 4 are each independently selected from the group consisting of H, halogen, C1-C6 straight or branched alkyl, halogenated C1-C6 straight or branched alkyl;
  • G 5 is selected from the group consisting of H, C1-C6 straight or branched alkyl, C1-C6 straight or branched alkylcarbonyl, C1-C6 straight or branched alkyl-hydroxy, C1-C6 Alkoxyalkyl, unsubstituted or alkyl substituted amine, C1-C8 cycloalkyl;
  • E 1 and E 2 are each independently selected from the group consisting of H, halogen, straight or branched alkyl, halogenated C1-C6 straight or branched alkyl;
  • E 3 is selected from the group consisting of H, C1-C6 linear alkyl or branched alkyl, C1-C6 straight or branched alkylcarbonyl, C1-C6 straight or branched alkylene-hydroxy, a C1-C6 alkoxyalkyl group, an unsubstituted or alkyl-substituted amine group, a C1-C8 cycloalkyl group;
  • R 13 , R 14 , R 15 and R 16 are each independently selected from the group consisting of H, C1-C6 straight or branched alkyl, C1-C6 straight or branched alkylcarbonyl, C1-C6 straight chain Or a branched alcohol group (alkylene-hydroxyl group), or R13 and R14, R15 and R16 are bonded to a carbon atom to form a 5- to 7-membered ring;
  • C0-C3 alkyl is an alkylene group having no or 1-3 carbon atoms
  • the C1-C6 alkyl group is an alkylene group having 1 to 6 carbon atoms.
  • L is selected from the group consisting of H, tetrahydropyranyl (THP);
  • Each X is independently selected from the group consisting of H, Cl, F, CN;
  • W, Y, Z are each independently selected from: N or CH;
  • Ring A is a substituted or unsubstituted 6-membered aryl group, or a substituted or unsubstituted 5 to 6-membered heteroaryl group, wherein the heteroaryl group contains at least one hetero atom selected from the group consisting of nitrogen and oxygen. Or sulfur;
  • M is selected from the group consisting of a substituted or unsubstituted C1-C4 alkylene group, or M is absent; said substitution means that one or more hydrogen atoms on the group are substituted with a substituent selected from the group consisting of: Halogen, unsubstituted or halogenated C1-C4 alkyl, unsubstituted or halogenated C1-C6 alkoxy, unsubstituted or halogenated C2-C6 alkoxyalkyl, unsubstituted or halogenated C3- C8 cycloalkyl, unsubstituted or halogenated C2-C4 alkylcarbonyl, unsubstituted or halogenated C1-C4 alkyl-hydroxy, unsubstituted or C1-C6 alkyl substituted amine.
  • a substituent selected from the group consisting of: Halogen, unsubstituted or halogenated C1-C4 alkyl,
  • Each X is independently selected from the group consisting of H, Cl, and F;
  • W, Y, Z are each independently selected from: N or CH;
  • Ring A is a group selected from the group consisting of: phenyl, pyrazolyl, pyridyl, thiazolyl, pyrimidine, pyrazine or piperidinyl;
  • M is selected from the group consisting of a substituted or unsubstituted C1-C3 alkylene group, or M is absent;
  • any one or more of the hydrogen atoms on the substituent is substituted with a substituent selected from the group consisting of halogen, unsubstituted or halogenated C1-C4 alkyl, unsubstituted or halogenated C2-C6.
  • a substituent selected from the group consisting of halogen, unsubstituted or halogenated C1-C4 alkyl, unsubstituted or halogenated C2-C6.
  • the compound of formula I is a compound shown in Table A below:
  • L, X, W, Y, Z, Ring A or R are the corresponding groups in the specific compounds described in the examples.
  • each group is as defined in claim 1.
  • the reaction in the step (a), is carried out in the presence of a copper salt; preferably, the copper salt is selected from the group consisting of CuI, Cu, CuCl, Cu 2 O , CuO, Cu(OAc) 2 , CuSO 4 ⁇ 5H 2 O, Cu(acac) 2 , CuCl 2 , CuSCN, or a combination thereof.
  • a copper salt is selected from the group consisting of CuI, Cu, CuCl, Cu 2 O , CuO, Cu(OAc) 2 , CuSO 4 ⁇ 5H 2 O, Cu(acac) 2 , CuCl 2 , CuSCN, or a combination thereof.
  • the reaction in the step (a), is carried out in the presence of a ligand; preferably, the ligand is a bidentate amine ligand; more preferably, the The ligand is selected from the group consisting of N1, N2-dimethyl-ethylenediamine, (1R, 2R)-(-)-N, N'-dimethyl-1,2-cyclohexanediamine, or a combination thereof .
  • the reaction in the step (a), is carried out in the presence of a base; preferably, the base is an inorganic base, more preferably selected from the group consisting of K 2 CO 3 K 3 PO 4 , Cs 2 CO 3 , or a combination thereof.
  • the base is an inorganic base, more preferably selected from the group consisting of K 2 CO 3 K 3 PO 4 , Cs 2 CO 3 , or a combination thereof.
  • the inert solvent is selected from the group consisting of toluene, dioxane, THF, DMF, or a combination thereof.
  • the method further includes the steps of:
  • L is selected from the group consisting of tetrahydropyranyl (THP);
  • the reaction in the step (b), is carried out in the presence of an acid; preferably, the acid is selected from the group consisting of hydrochloric acid, p-toluenesulfonic acid, TFA, or combination.
  • an acid preferably, the acid is selected from the group consisting of hydrochloric acid, p-toluenesulfonic acid, TFA, or combination.
  • the inert solvent is selected from the group consisting of dichloromethane, methanol, ethanol, isopropanol, n-butanol, tert-butanol, isobutanol, Or a combination thereof.
  • the disease associated with the FGFR activity or expression amount is a tumor, preferably a tumor selected from the group consisting of endometrial cancer, breast cancer, gastric cancer, bladder cancer, myeloma, and liver cancer.
  • the FGFR kinase is selected from the group consisting of FGFR1, FGFR2, FGFR3, or a combination thereof.
  • the tumor cell is a leukemia cell line; preferably a myeloid leukemia cell line; more preferably an acute myeloid leukemia cell line KG1 cell.
  • a pharmaceutical composition comprising: (i) an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof; and (ii) pharmaceutically acceptable a.
  • the effective amount means a therapeutically effective amount or an inhibitory effective amount, preferably 0.01 to 99.99%.
  • the pharmaceutical composition is for inhibiting the activity of FGFR kinase.
  • the pharmaceutical composition is for treating a disease associated with FGFR kinase activity or expression.
  • a fifth aspect of the invention provides a method of inhibiting FGFR kinase activity, comprising the steps of: administering to a subject, an inhibitory effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, according to the first aspect of the invention, Or administering to the subject, an inhibitory effective amount of the pharmaceutical composition of the fourth aspect of the invention.
  • the inhibition is non-therapeutic inhibition in vitro.
  • an inhibitory effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof when administered to a subject, the inhibitory effective amount is from 0.001 to 500 nmol/L, The preferred ground is 0.01-200 nmol/L.
  • a sixth aspect of the invention provides a method of treating a disease associated with FGFR kinase activity or expression, characterized in that the method comprises: administering to a subject a therapeutically effective amount of the first aspect of the invention A compound of formula I, or a pharmaceutical composition according to the fourth invention of the invention.
  • the disease associated with FGFR activity or expression is a tumor, preferably selected from the group consisting of Group of tumors: endometrial cancer, breast cancer, stomach cancer, bladder cancer, myeloma, liver cancer.
  • a seventh aspect of the invention provides a method of inhibiting tumor cells in vitro, the method comprising: administering an inhibitory effective amount of a compound of formula I according to the first aspect of the invention to a subject, or a fourth aspect of the invention
  • the pharmaceutical composition of aspect is provided.
  • the inventors have conducted long-term and intensive studies to prepare a class of compounds having the structure shown in Formula I, and have found that they have FGFR kinase inhibitory activity. And the compound can inhibit the activity of FGFR kinase activity or expression at a very low concentration (as low as ⁇ 100nmol/L), that is, an inhibitory effect on a series of FGFR kinases, and the inhibitory activity is quite excellent. Such as tumors. Based on the above findings, the inventors completed the present invention.
  • C1-C6 alkyl refers to a straight or branched alkyl group having from 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, A sec-butyl group, a tert-butyl group, or the like.
  • C1-C6 alkylene refers to the above C1 ⁇ C6 alkyl group formed after the loss of a hydrogen atom, for example -CH 2 -, - CH 2 -CH 2 -, or the like.
  • C6-C10 arylene refers to a group formed by an aryl group having 6 to 10 carbon atoms which loses a hydrogen atom, and includes a monocyclic or bicyclic arylene group such as a phenylene group, a naphthylene group, or the like. Group.
  • 6-membered aryl refers to phenyl
  • 5-8 membered aryl refers to a carbon-unsaturated substituent of a 5-8 membered ring, such as a phenyl group, or the like.
  • 5- to 8-membered heteroaryl refers to a non-saturated ring-based substituent having a heterocyclic ring selected from O, S, N or P on a ring system having 5-8 members, such as pyridyl, Thienyl, or a similar group.
  • saturated 3- to 12-membered carbocyclic ring means a saturated carbocyclic ring having 3 to 12 carbon atoms, such as a cyclohexyl group, or the like.
  • 3- to 12-membered heterocyclic ring refers to a saturated ring system substituent having a hetero atom of one or more selected from O, S, N or P in a ring system having 3 to 12 members, such as piperidinyl, pyrrolyl. , or a similar group.
  • halogen refers to F, Cl, Br and I.
  • the terms "containing”, “comprising” or “including” mean that the various ingredients may be used together in the mixture or composition of the present invention. Therefore, the terms “consisting essentially of” and “consisting of” are encompassed by the term “contains.”
  • the term "pharmaceutically acceptable” ingredient means a substance which is suitable for use in humans and/or animals without excessive adverse side effects (such as toxicity, irritation, and allergic reaction), that is, a reasonable benefit/risk ratio.
  • the term "effective amount" means an amount of a therapeutic agent that treats, alleviates or prevents a target disease or condition, or an amount that exhibits a detectable therapeutic or prophylactic effect.
  • the precise effective amount for a subject will depend on the size and health of the subject, the nature and extent of the condition, and the combination of therapeutic and/or therapeutic agents selected for administration. Therefore, it is useless to specify an accurate effective amount in advance. However, for a given condition, routine experimentation can be used to determine the effective amount that the clinician can determine.
  • substituted means that one or more hydrogen atoms on the group are selected from Substituents of the group are substituted: halogen, unsubstituted or halogenated C1-C6 alkyl, unsubstituted or halogenated C2-C6 acyl, unsubstituted or halogenated C1-C6 alkyl-hydroxy.
  • each of the chiral carbon atoms may be optionally in the R configuration or the S configuration, or a mixture of the R configuration and the S configuration.
  • compound of the invention refers to a compound of formula I.
  • the term also encompasses various crystalline forms, pharmaceutically acceptable salts, hydrates or solvates of the compounds of formula I.
  • the term "pharmaceutically acceptable salt” refers to a salt of the compound of the invention formed with an acid or base suitable for use as a medicament.
  • Pharmaceutically acceptable salts include inorganic and organic salts.
  • a preferred class of salts are the salts of the compounds of the invention with acids.
  • Suitable acids for forming salts include, but are not limited to, mineral acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, Organic acids such as maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzoic acid, and benzenesulfonic acid; and acidic amino acids such as aspartic acid and glutamic acid.
  • mineral acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid,
  • Organic acids such as maleic acid, lactic acid, malic acid, tartaric acid,
  • L is selected from the group consisting of H, tetrahydropyranyl (THP);
  • Each X is independently selected from the group consisting of Cl, F, H, CN;
  • W, Y, Z are each independently selected from: N or CH;
  • Ring A is a non-, substituted or unsubstituted 5-8-membered aryl group, or a substituted or unsubstituted 5- to 8-membered heteroaryl group, wherein the heteroaryl group contains at least one hetero atom selected from the group consisting of a nitrogen, oxygen, or sulfur; a substituted or unsubstituted 3 to 12 membered saturated heterocyclic ring or carbocyclic ring, wherein said heterocyclic ring comprises at least one hetero atom selected from the group consisting of nitrogen, oxygen, or sulfur; Or
  • R is H or a substituted or unsubstituted group selected from the group consisting of:
  • M is selected from the group consisting of: a substituted, unsubstituted or unsubstituted C1-C6 alkylene group, a substituted or unsubstituted C6-C10 arylene group, a substituted or unsubstituted C1-C10 heteroarylene group;
  • substitution means that one or more hydrogen atoms on the group are substituted with a substituent selected from the group consisting of halogen, unsubstituted or halogenated C1-C6 alkyl, unsubstituted or halogenated C2-C6 acyl, Unsubstituted or halogenated C1-C6 alkyl-hydroxy.
  • the ring A is a heteroaryl group selected from the group consisting of:
  • Q 1 , Q 2 , Q 3 , Q 4 are each independently selected from: N or CH;
  • B 1 , B 2 , B 3 , and B 4 are each independently selected from: N or CH.
  • the ring A is a heteroaryl group selected from the group consisting of:
  • R is a substituted or unsubstituted group selected from the group consisting of:
  • R 1 , R 2 , R 3 , R 4 are each independently selected from the group consisting of H, halogen, C1-C6 linear alkyl or branched alkyl, halogenated C1-C6 linear alkyl or branched alkane base;
  • R 5 is selected from the group consisting of H, a C1-C6 linear alkyl or branched alkyl group, a C1-C6 linear or branched acyl group, and a C1-C6 linear or branched alkylene-hydroxy group.
  • R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 are each independently selected from the group consisting of H, C1-C6 linear alkyl or branched alkyl, C1-C6 straight or branched Chain acyl group, C1-C6 linear or branched alcohol group (alkylene-hydroxyl group);
  • G 1 , G 2 , G 3 , G 4 are each independently selected from the group consisting of H, halogen, C1-C6 linear alkyl or branched alkyl, halogenated C1-C6 linear alkyl or branched alkane Base or
  • G 5 is selected from the group consisting of H, C1-C6 linear alkyl or branched alkyl, C1-C6 straight or branched acyl, C1-C6 straight or branched alkyl-hydroxy;
  • E 1 and E 2 are each independently selected from the group consisting of H, halogen, linear alkyl or branched alkyl, halogenated C1-C6 linear alkyl or branched alkyl;
  • E 3 is selected from the group consisting of H, C1-C6 linear alkyl or branched alkyl, C1-C6 straight or branched acyl, C1-C6 straight or branched alkylene-hydroxy;
  • R 13 , R 14 , R 15 and R 16 are each independently selected from the group consisting of H, C1-C6 linear alkyl or branched alkyl, C1-C6 straight or branched acyl, C1-C6 straight chain Or branched alcohol groups (alkylene-hydroxy);
  • C0-C3 alkyl is an alkylene group having no or 1-3 carbon atoms
  • the C1-C6 alkyl group is an alkylene group having 1 to 6 carbon atoms.
  • L is selected from the group consisting of H, tetrahydropyranyl (THP);
  • Each X is independently selected from the group consisting of H, Cl, F, CN;
  • W, Y, Z are each independently selected from: N or CH;
  • Ring A is a substituted or unsubstituted 6-membered aryl group, or a substituted or unsubstituted 5 to 6-membered heteroaryl group, wherein the heteroaryl group contains at least one hetero atom selected from the group consisting of nitrogen and oxygen. Or sulfur;
  • M is selected from the group consisting of a substituted or unsubstituted C1-C4 alkylene group, or M is absent;
  • substitution means that one or more hydrogen atoms on the group are substituted with a substituent selected from the group consisting of halogen, unsubstituted or halogenated C1-C4 alkyl, unsubstituted or halogenated C2-C4 acyl, Unsubstituted or halogenated C1-C4 alkyl-hydroxy.
  • L is H
  • Each X is independently selected from the group consisting of H, Cl, and F;
  • W, Y, Z are each independently selected from: N or CH;
  • Ring A is a group selected from the group consisting of: phenyl, pyrazolyl, pyridyl, thiazolyl, piperidinyl;
  • M is selected from the group consisting of a substituted or unsubstituted C1-C3 alkylene group, or M is absent;
  • substitution means that one or more hydrogen atoms on the group are substituted with a substituent selected from the group consisting of halogen, unsubstituted or halogenated C1-C4 alkyl, unsubstituted or halogenated C2-C4 acyl, Unsubstituted or halogenated C1-C4 alkyl-hydroxy.
  • the compound of formula I is a compound selected from the group consisting of:
  • each reaction is usually carried out in an inert solvent at room temperature to reflux temperature.
  • the reaction time is usually from 0.1 to 60 hours, preferably from 0.5 to 48 hours.
  • a preferred method of preparing a compound of formula I comprises the steps of:
  • the reaction is carried out in the presence of a copper salt; preferably, the copper salt is selected from, but not limited to, the following groups: CuI, Cu, CuCl, Cu 2 O, CuO, Cu(OAc) 2 , CuSO 4 ⁇ 5H 2 O, Cu(acac) 2 , CuCl 2 , CuSCN, or a combination thereof.
  • the copper salt is selected from, but not limited to, the following groups: CuI, Cu, CuCl, Cu 2 O, CuO, Cu(OAc) 2 , CuSO 4 ⁇ 5H 2 O, Cu(acac) 2 , CuCl 2 , CuSCN, or a combination thereof.
  • the reaction is carried out in the presence of a ligand; preferably, the ligand is a bidentate amine ligand; more preferably, the ligand is selected from (but not limited to) The lower group: N1, N2-dimethyl-ethylenediamine, (1R, 2R)-(-)-N,N'-dimethyl-1,2-cyclohexanediamine, or a combination thereof.
  • the reaction is carried out in the presence of a base; preferably, the base is an inorganic base, more preferably selected from, but not limited to, the following group: K 2 CO 3 , K 3 PO 4 , Cs 2 CO 3 , or a combination thereof.
  • the base is an inorganic base, more preferably selected from, but not limited to, the following group: K 2 CO 3 , K 3 PO 4 , Cs 2 CO 3 , or a combination thereof.
  • the inert solvent is selected from, but not limited to, the lower group: toluene, dioxane, THF, DMF, or a combination thereof.
  • the method further includes the steps of:
  • the reaction is carried out in the presence of an acid; preferably, the acid is selected from, but not limited to, the lower group: hydrochloric acid, p-toluenesulfonic acid, TFA, or a combination thereof.
  • an acid preferably, the acid is selected from, but not limited to, the lower group: hydrochloric acid, p-toluenesulfonic acid, TFA, or a combination thereof.
  • the inert solvent is selected from, but not limited to, the following group: dichloromethane, methanol, ethanol, isopropanol, n-butanol, tert-butanol, isobutanol, or a combination thereof .
  • a more preferred preparation method comprises the following steps:
  • Compound A2 can be reacted with Compound A1 and DHP in an inert solvent (DCM, THF, etc.) under the catalysis of an acid such as, but not limited to, p-toluenesulfonic acid, trifluoroacetic acid.
  • an inert solvent DCM, THF, etc.
  • Compound A4 may be subjected to Suzuki coupling by a corresponding boronic acid or ester in an inert solvent (such as dioxane and water, toluene and water, DMSO, THF, DMF, etc.) in a catalyst (such as four ( Triphenylphosphine)palladium, tris(dibenzylideneacetone)dipalladium (Pd 2 (dba) 3 ), bis(dibenzylideneacetone)palladium, dichlorobis(triphenylphosphine)palladium, triphenyl Palladium phosphinate, bis(tri-o-phenylmethylphosphine)palladium dichloride, 1,2-bis(diphenylphosphino)ethanepalladium dichloride, etc.) and bases (such as potassium carbonate, potassium fluoride, fluorine) Antimony, sodium fluoride, potassium phosphate, potassium hydrate hydrate, sodium carbonate, sodium hydrogencarbonate
  • Compound A5 can be obtained by slowly dropping SO 2 Cl 2 from compound A4 in an inert solvent (dichloromethane, THF, acetonitrile) and stirring at room temperature.
  • an inert solvent dichloromethane, THF, acetonitrile
  • Compound A6 can be obtained by deprotecting compound A5, and adding an acid (such as hydrochloric acid, in an inert solvent (such as dichloromethane, methanol, ethanol, isopropanol, n-butanol, tert-butanol, isobutanol, etc.) Toluenesulfonic acid, TFA) gave compound A6.
  • an acid such as hydrochloric acid
  • an inert solvent such as dichloromethane, methanol, ethanol, isopropanol, n-butanol, tert-butanol, isobutanol, etc.
  • Compound A7 may be added with compound A6, iodine and NaOH in an inert solvent (1,4-dioxane, DMF, etc.). Stir at room temperature.
  • Compound A8 can be reacted with Compound A7 and DHP in an inert solvent (DCM, THF, etc.) under the catalysis of an acid such as, but not limited to, p-toluenesulfonic acid, trifluoroacetic acid.
  • an inert solvent DCM, THF, etc.
  • Compound A10 may be amidated by aromatization of compound A8 and compound A9.
  • the reaction is carried out in the presence of one or more of the following: a copper salt, which may be, but not limited to, CuI, Cu, CuCl, Cu 2 O, CuO, Cu(OAc) 2 , CuSO 4 ⁇ 5H 2 O, Cu(acac) 2 , CuCl 2 , CuSCN, or a combination thereof.
  • a copper salt which may be, but not limited to, CuI, Cu, CuCl, Cu 2 O, CuO, Cu(OAc) 2 , CuSO 4 ⁇ 5H 2 O, Cu(acac) 2 , CuCl 2 , CuSCN, or a combination thereof.
  • a ligand which may be a bidentate amine ligand, including but not limited to N1, N2-dimethyl-ethylenediamine, (1R, 2R)-(-)-N, N'-dimethyl- 1,2-cyclohexanediamine, a base
  • the base may be, but not limited to, an inorganic base such as K 2 CO 3 , K 3 PO 4 , Cs 2 CO 3
  • the solvent of the reaction may be, but not limited to, toluene, Oxycyclohexane, THF, DMF.
  • Compound A11 can be obtained by deprotecting compound A10 using an appropriate acid such as, but not limited to, hydrochloric acid, p-toluenesulfonic acid, TFA in an inert solvent (such as dichloromethane, methanol, ethanol, isopropanol, n-butyl)
  • an inert solvent such as dichloromethane, methanol, ethanol, isopropanol, n-butyl
  • Compound 11 is obtained by alcohol, tert-butanol, isobutanol or the like.
  • the disease associated with the FGFR activity or expression amount is a tumor, preferably a tumor selected from the group consisting of endometrial cancer, breast cancer, gastric cancer, bladder cancer, myeloma, and liver cancer.
  • the FGFR kinase is selected from the group consisting of FGFR1, FGFR2, FGFR3, or a combination thereof.
  • the tumor cell is a leukemia cell line; preferably a myeloid leukemia cell line; more preferably an acute myeloid leukemia cell line KG1 cell.
  • the compounds of formula I of the present invention are useful in the preparation of a pharmaceutical composition comprising: (i) an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof; and (ii) pharmaceutically acceptable a.
  • the effective amount refers to a therapeutically effective amount or an inhibitory effective amount.
  • the pharmaceutical composition is for inhibiting the activity of FGFR kinase.
  • the pharmaceutical composition is for treating a disease associated with FGFR kinase activity or expression.
  • the compounds of the formula I according to the invention may also be used in a method for inhibiting the activity of FGFR kinase, characterized by comprising the step of administering an inhibitory effective amount of a compound of the formula I according to claim 1 or a pharmaceutically acceptable salt thereof, to a subject. Or administering an inhibitory effective amount of the pharmaceutical composition of claim 7 to the subject.
  • the inhibition is non-therapeutic inhibition in vitro.
  • an inhibitory effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof when administered to a subject, the inhibitory effective amount is from 0.001 to 500 nmol/L, The preferred ground is 0.01-200 nmol/L.
  • the invention also provides a method of treating a disease associated with FGFR kinase activity or expression, the method comprising: administering to a subject a therapeutically effective amount of a compound of formula I, or said compound comprising formula I as effective A pharmaceutical composition of the ingredients.
  • the disease associated with the FGFR activity or expression amount is a tumor, preferably a tumor selected from the group consisting of endometrial cancer, breast cancer, gastric cancer, bladder cancer, myeloma, and liver cancer.
  • the compound of the present invention has excellent inhibitory activity against FGFR kinase (Kinase) such as FGFR1, FGFR2, FGFR3, the compound of the present invention and various crystal forms thereof, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates
  • a pharmaceutical composition containing the compound of the present invention as a main active ingredient can be used for the treatment, prevention, and alleviation of diseases associated with FGFR activity or expression.
  • the compounds of the invention are useful in the treatment The following diseases: endometrial cancer, breast cancer, stomach cancer, bladder cancer, myeloma, liver cancer and so on.
  • compositions of the present invention comprise a safe or effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
  • safe and effective amount it is meant that the amount of the compound is sufficient to significantly improve the condition without causing serious side effects.
  • the pharmaceutical compositions contain from 1 to 2000 mg of the compound of the invention per agent, more preferably from 5 to 200 mg of the compound of the invention per agent.
  • the "one dose” is a capsule or tablet.
  • “Pharmaceutically acceptable carrier” means: one or more compatible solid or liquid fillers or gel materials which are suitable for human use and which must be of sufficient purity and of sufficiently low toxicity. By “compatibility” it is meant herein that the components of the composition are capable of intermingling with the compounds of the invention and with each other without significantly reducing the efficacy of the compound.
  • pharmaceutically acceptable carriers are cellulose and its derivatives (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid).
  • magnesium stearate magnesium stearate
  • calcium sulfate vegetable oil (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyol (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifier Wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
  • the mode of administration of the compound or pharmaceutical composition of the present invention is not particularly limited, and representative modes of administration include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration. .
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or mixed with: (a) a filler or compatibilizer, for example, Starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and gum arabic; (c) humectants, For example, glycerin; (d) a disintegrant such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) a slow solvent such as paraffin; (f) Absorbing accelerators, for example, quaternary amine compounds; (g) wetting agents, such as cetyl alcohol and
  • Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other materials known in the art. They may contain opacifying agents and the release of the active compound or compound in such compositions may be released in a portion of the digestive tract in a delayed manner. Examples of embedding components that can be employed are polymeric and waxy materials. If necessary, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs.
  • the liquid dosage form may contain inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or a mixture of these substances.
  • inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethyl
  • compositions may contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents, and flavoring agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents, and flavoring agents.
  • the suspension may contain suspending agents, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these and the like.
  • suspending agents for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these and the like.
  • compositions for parenteral injection may comprise a physiologically acceptable sterile aqueous or nonaqueous solution, dispersion, suspension or emulsion, and a sterile powder for reconstitution into a sterile injectable solution or dispersion.
  • Suitable aqueous and nonaqueous vehicles, diluents, solvents or vehicles include water, ethanol, polyols, and suitable mixtures thereof.
  • Dosage forms for the compounds of the invention for topical administration include ointments, powders, patches, propellants and inhalants.
  • the active ingredient is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or, if necessary, propellants.
  • the compounds of the invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
  • a safe and effective amount of a compound of the invention is administered to a mammal (e.g., a human) in need of treatment wherein the dosage is a pharmaceutically effective effective dosage, for a 60 kg body weight
  • the dose to be administered is usually from 1 to 2000 mg, preferably from 5 to 500 mg.
  • specific doses should also consider factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled physician.
  • FGFR inhibitor having a novel structure and inhibiting the activity of various FGFR kinases at very low concentrations.
  • a class of pharmaceutical compositions for treating diseases associated with FGFR kinase activity is provided.
  • the enzyme reaction substrate Poly(Glu, Tyr) 4:1 was diluted with potassium-free PBS (10 mM sodium phosphate buffer, 150 mM NaCl, pH 7.2-7.4) to 20 ⁇ g/mL, and 125 ⁇ L/well coated with the ELISA plate. The reaction was carried out at 37 ° C for 12-16 hours. After discarding the liquid in the well, the plate was washed, and the plate was washed three times with 200 ⁇ L/well of T-PBS (PBS containing 0.1% Tween-20) for 5 minutes each time. The plate was dried in an oven at 37 ° C for 1-2 hours.
  • reaction buffer 50 mM HEPES pH 7.4, 50 mM MgCl 2 , 0.5 mM MnCl 2 , 0.2 mM Na 3 VO 4 , 1 mM DTT
  • the compound is diluted with DMSO to a suitable concentration, 1 ⁇ L/well or containing the corresponding concentration of DMSO (negative control well), and then added with each kinase kinase domain recombinant protein diluted with 49 ⁇ L of reaction buffer to initiate the reaction, each experiment requires ATP-free Two wells of the control well.
  • the reaction was carried out for 1 hour at 37 ° C on a shaker (100 rpm).
  • the plate was washed three times with T-PBS.
  • One anti-PY99 dilution was added to 100 ⁇ L/well, and the reaction was shaken at 37 ° C for 0.5 hour.
  • the plate was washed three times with T-PBS.
  • a second anti-horseradish peroxidase-labeled goat anti-mouse IgG dilution was added at 100 ⁇ L/well, and shaken at 37 ° C for 0.5 hour.
  • the plate was washed three times with T-PBS.
  • the inhibition rate of the sample is obtained by the following formula:
  • IC 50 values were obtained by four-parameter regression using software attached to the microplate reader.
  • Some IC 50 information is provided in the table below.
  • the symbol + represents an IC 50 of less than 100 nm
  • the symbol ++ represents an IC 50 of 100 nm to 500 nm
  • N/A represents no data.
  • CCK-8 cell counting kit for growth inhibition of acute myeloid leukemia cell line KG1 cells (FGFR1 fusion protein expressed in the cytoplasm, FGFR1-dependent tumor cell line, purchased from ATCC cell bank) Detection.
  • the specific steps are as follows: KG1 cells in logarithmic growth phase were inoculated into 96-well culture plates at a suitable density, 90 ⁇ L per well, and after incubation overnight, different concentrations of compounds were added for 72 hr, and a solvent control group (negative control) was set. After the compound was treated for 72h, the effect of the compound on cell proliferation was detected by CCK-8 cell counting kit (Dojindo).
  • inhibition rate (%) (OD negative control well-OD administration well) / OD negative control well ⁇ 100%.
  • IC 50 values were obtained by four-parameter regression using software attached to the microplate reader.
  • the IC 50 values for some of the compounds are provided in the table below.
  • the symbol + represents an IC 50 of less than 200 nm
  • the symbol ++ represents an IC 50 of 200 nm to 1000 nm.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/CN2015/087556 2014-08-19 2015-08-19 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用 WO2016026445A1 (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES15833329T ES2904544T3 (es) 2014-08-19 2015-08-19 Compuestos de indazol como inhibidores de la cinasa FGFR, preparación y uso de los mismos
KR1020177007663A KR102022866B1 (ko) 2014-08-19 2015-08-19 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용
BR112017003312-7A BR112017003312B1 (pt) 2014-08-19 2015-08-19 Compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
US15/504,854 US10562900B2 (en) 2014-08-19 2015-08-19 Indazole compounds as FGFR kinase inhibitor, preparation and use thereof
AU2015306561A AU2015306561B2 (en) 2014-08-19 2015-08-19 Indazole compounds as FGFR kinase inhibitor, preparation and use thereof
CA2958503A CA2958503C (en) 2014-08-19 2015-08-19 Indazole compounds as fgfr kinase inhibitor, preparation and use thereof
EP15833329.4A EP3184521B1 (en) 2014-08-19 2015-08-19 Indazole compounds as fgfr kinase inhibitors, preparation and use thereof
KR1020197026420A KR102166002B1 (ko) 2014-08-19 2015-08-19 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용
MX2017002206A MX2017002206A (es) 2014-08-19 2015-08-19 Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
MYPI2017000250A MY188447A (en) 2014-08-19 2015-08-19 Indazole compounds as fger kinase inhibitor, preparation and use thereof
RU2017105781A RU2719428C2 (ru) 2014-08-19 2015-08-19 Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение
JP2017509744A JP6445684B2 (ja) 2014-08-19 2015-08-19 Ｆｇｆｒキナーゼ阻害剤としてのインダゾール系化合物およびその製造と使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201410409467 2014-08-19
CN201410409467.1 2014-08-19
CN201510073179 2015-02-11
CN201510073179.8 2015-02-11

Publications (1)

Publication Number Publication Date
WO2016026445A1 true WO2016026445A1 (zh) 2016-02-25

Family

ID=55350206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/087556 WO2016026445A1 (zh) 2014-08-19 2015-08-19 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用

Country Status (14)

Country Link
US (1) US10562900B2 (pt)
EP (1) EP3184521B1 (pt)
JP (1) JP6445684B2 (pt)
KR (2) KR102022866B1 (pt)
CN (1) CN105524048B (pt)
AU (1) AU2015306561B2 (pt)
BR (1) BR112017003312B1 (pt)
CA (1) CA2958503C (pt)
ES (1) ES2904544T3 (pt)
MX (1) MX2017002206A (pt)
MY (1) MY188447A (pt)
PE (1) PE20170774A1 (pt)
RU (1) RU2719428C2 (pt)
WO (1) WO2016026445A1 (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105601617A (zh) * 2016-03-24 2016-05-25 山东省科学院生物研究所 一种邻二氮杂环化合物及其制备方法与应用
WO2016188214A1 (zh) * 2015-05-27 2016-12-01 上海海和药物研究开发有限公司 一种新型激酶抑制剂的制备及其应用
JP2019524883A (ja) * 2016-08-09 2019-09-05 広州諾誠健華医薬科技有限公司Ｇｕａｎｇｚｈｏｕ Ｉｎｎｏｃａｒｅ Ｐｈａｒｍａ Ｔｅｃｈ Ｃｏ．，Ｌｔｄ． Ｆｇｆｒ阻害剤としての複素環化合物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
RS56924B9 (sr) 2013-04-19 2019-09-30 Incyte Holdings Corp Biciklični heterocikli kao fgfr inhibitori
WO2016026445A1 (zh) * 2014-08-19 2016-02-25 上海海和药物研究开发有限公司 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN110317173B (zh) * 2018-03-30 2022-10-11 上海奕拓医药科技有限责任公司 用作fgfr不可逆抑制剂的酰胺基吡唑类化合物
EP3788047A2 (en) 2018-05-04 2021-03-10 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
CN108570049A (zh) * 2018-07-24 2018-09-25 上海毕得医药科技有限公司 一种6-氯-1氢-吡唑并[3,4-b]吡啶的合成方法
CN110857300B (zh) * 2018-08-23 2021-11-05 上海凌达生物医药有限公司 一类稠环三氮唑类化合物、制备方法和用途
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022004513A (es) * 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021104461A1 (zh) * 2019-11-29 2021-06-03 南京明德新药研发有限公司 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CN112521336B (zh) * 2020-02-21 2023-03-28 温州医科大学 一种吲唑类、吡咯并吡啶类化合物及其应用
US20230250106A1 (en) * 2020-07-15 2023-08-10 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
EP4182310A1 (en) * 2020-07-15 2023-05-24 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN113735774B (zh) * 2021-08-31 2023-06-09 四川大学华西医院 一种多激酶抑制剂yth-17的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
CN101962365A (zh) * 2002-03-11 2011-02-02 安万特医药股份有限公司 作为蛋白激酶抑制剂的氨基吲唑衍生物
WO2014052563A2 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20140171405A1 (en) * 2012-12-19 2014-06-19 Incyte Corporation Fused Pyrazoles as FGFR Inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
MX2015007936A (es) * 2012-12-19 2016-03-11 Novartis Ag Inhibidores de autotaxina.
WO2016026445A1 (zh) * 2014-08-19 2016-02-25 上海海和药物研究开发有限公司 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
CN101962365A (zh) * 2002-03-11 2011-02-02 安万特医药股份有限公司 作为蛋白激酶抑制剂的氨基吲唑衍生物
WO2014052563A2 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20140171405A1 (en) * 2012-12-19 2014-06-19 Incyte Corporation Fused Pyrazoles as FGFR Inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU, JIAN ET AL.: "Design, Synthesis and Biological Evaluation of Novel FGFR Inhibitors Bearing an Indazole Scaffold", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 13, no. 28, 1 June 2015 (2015-06-01), pages 7643 - 7654, XP055332373 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016188214A1 (zh) * 2015-05-27 2016-12-01 上海海和药物研究开发有限公司 一种新型激酶抑制剂的制备及其应用
CN105601617A (zh) * 2016-03-24 2016-05-25 山东省科学院生物研究所 一种邻二氮杂环化合物及其制备方法与应用
CN105601617B (zh) * 2016-03-24 2019-02-22 山东省科学院生物研究所 一种邻二氮杂环化合物及其制备方法与应用
JP2019524883A (ja) * 2016-08-09 2019-09-05 広州諾誠健華医薬科技有限公司Ｇｕａｎｇｚｈｏｕ Ｉｎｎｏｃａｒｅ Ｐｈａｒｍａ Ｔｅｃｈ Ｃｏ．，Ｌｔｄ． Ｆｇｆｒ阻害剤としての複素環化合物

Also Published As

Publication number Publication date
KR102166002B1 (ko) 2020-10-15
EP3184521B1 (en) 2021-10-06
EP3184521A4 (en) 2018-01-03
KR20190105679A (ko) 2019-09-17
RU2719428C2 (ru) 2020-04-17
MX2017002206A (es) 2018-01-23
US10562900B2 (en) 2020-02-18
KR102022866B1 (ko) 2019-09-19
AU2015306561B2 (en) 2018-03-15
CN105524048B (zh) 2019-11-12
CA2958503C (en) 2021-01-19
MY188447A (en) 2021-12-09
PE20170774A1 (es) 2017-07-04
RU2017105781A3 (pt) 2019-01-21
CN105524048A (zh) 2016-04-27
KR20170069199A (ko) 2017-06-20
EP3184521A1 (en) 2017-06-28
JP6445684B2 (ja) 2018-12-26
CA2958503A1 (en) 2016-02-25
BR112017003312B1 (pt) 2023-05-02
US20170275291A1 (en) 2017-09-28
JP2017532293A (ja) 2017-11-02
AU2015306561A1 (en) 2017-04-06
ES2904544T3 (es) 2022-04-05
RU2017105781A (ru) 2018-09-20
BR112017003312A2 (pt) 2018-02-27

Similar Documents

Publication Publication Date Title
WO2016026445A1 (zh) 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
CN109310690B (zh) 异喹啉-3-基甲酰胺类及其制备和其用途
JP6666263B2 (ja) グルタミナーゼの新規阻害剤
WO2016173557A1 (zh) 一类具有激酶抑制活性的化合物、制备方法和用途
WO2013170770A1 (zh) 具有抗肿瘤活性的乙炔衍生物
EP3141552A1 (en) Thienopyrimidine derivatives having inhibitory activity for protein kinase
KR20120034729A (ko) 야누스 키나제 억제제 화합물 및 방법
WO2016011979A1 (zh) 2，4-二取代7H-吡咯并[2，3-d]嘧啶衍生物、其制法与医药上的用途
WO2018010514A1 (zh) 作为fgfr抑制剂的杂环化合物
WO2018145525A1 (zh) 吡咯并芳杂环类化合物及其制备方法和医药用途
WO2018121400A1 (zh) 酰胺及硫代酰胺类衍生物及其制备方法和应用
WO2019085894A1 (zh) 一类含氮稠环化合物及其制备方法和用途
WO2020215998A1 (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
CN112313207A (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
WO2016188214A1 (zh) 一种新型激酶抑制剂的制备及其应用
WO2018228275A1 (zh) 作为mnk抑制剂的杂环化合物
WO2010064737A1 (ja) 複素環化合物およびその用途
CN115322158B (zh) 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物
WO2023036252A1 (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
WO2016165657A1 (zh) 激酶抑制剂的制备及应用
AU2005211493A1 (en) Pyrrolo pyrimidine derivatives useful for treating proliferative diseases
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
TWI820414B (zh) 喹唑啉類化合物、製備方法及其應用
WO2022194265A1 (zh) 一种喹唑啉类化合物、组合物及其应用
JP2010018601A (ja) 複素環化合物、その製造法および用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15833329

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017509744

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2958503

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 000231-2017

Country of ref document: PE

Ref document number: 15504854

Country of ref document: US

Ref document number: MX/A/2017/002206

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017003312

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2015833329

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015833329

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20177007663

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2017105781

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015306561

Country of ref document: AU

Date of ref document: 20150819

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112017003312

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112017003312

Country of ref document: BR

Free format text: EM ADITAMENTO A EXIGENCIA PUBLICADA NA RPI 2447, EM 28/11/2017, SOLICITA-SE QUE A RESPOSTA SEJA ENCAMINHADA DEVIDAMENTE, POR MEIO DA GRU CODIGO 207, ESPECIFICA PARA ESSE TIPO DE SERVICO.

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112017003312

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017003312

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170217